{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-366931","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2026-08-26T17:33:35+00:00","discovered_at":"2026-08-26T17:35:00.618168+00:00","generated_at":"2026-08-26T17:35:03.760572+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"FDA approves Revolution Medicines' RASONQUE for metastatic pancreatic adenocarcinoma","bullets":["FDA approved RASONQUE (daraxonrasib) on Aug 26, 2026 for adult patients with metastatic pancreatic adenocarcinoma after prior systemic therapy or ineligible for multiagent therapy.","Approval based on RASolute 302, a global randomized Phase 3 trial vs investigator's choice of cytotoxic chemotherapy in previously treated patients.","Once-daily oral RASONQUE tablets now available in the U.S. for eligible patients; wholesale acquisition cost $39,800 for 30-day supply.","This is the first FDA approval for Revolution Medicines' RAS inhibitor, marking a major commercial milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-366931","json":"https://secwatch.observer/filing/0001193125-26-366931.json","markdown":"https://secwatch.observer/filing/0001193125-26-366931.md","text":"https://secwatch.observer/filing/0001193125-26-366931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/0001193125-26-366931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/rvmd-20260826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T17:35:03.760572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}